Travere Therapeutics, Inc.
TVTX
$62.14
$0.711.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.80M | -37.10M | 2.73M | 25.71M | -12.76M |
| Total Depreciation and Amortization | 4.23M | 25.21M | 18.14M | 15.79M | 14.02M |
| Total Amortization of Deferred Charges | -- | -- | 1.64M | -- | -- |
| Total Other Non-Cash Items | 60.14M | 16.64M | -14.49M | 10.16M | 9.36M |
| Change in Net Operating Assets | 28.50M | -45.12M | 52.67M | -37.33M | -5.64M |
| Cash from Operations | 58.07M | -40.37M | 60.68M | 14.32M | 4.98M |
| Capital Expenditure | -- | -- | 375.00K | -140.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -206.29M | 21.55M | -105.21M | 86.73M | 4.85M |
| Cash from Investing | -206.29M | 21.55M | -104.84M | 86.59M | 4.85M |
| Total Debt Issued | 525.00M | -- | -- | -- | -- |
| Total Debt Repaid | -350.89M | -- | 0.00 | -68.90M | -- |
| Issuance of Common Stock | 30.20M | 4.73M | 27.20M | 4.09M | 2.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.80M | -525.00K | -525.00K | -525.00K | -525.00K |
| Cash from Financing | 187.52M | 4.20M | 26.68M | -65.34M | 1.48M |
| Foreign Exchange rate Adjustments | 72.00K | -60.00K | -413.00K | 207.00K | 1.95M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 39.37M | -14.67M | -17.90M | 35.78M | 13.26M |